image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 2.68
-1.83 %
$ 69.7 M
Market Cap
-0.7
P/E
1. INTRINSIC VALUE

Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples.[ Read More ]

The intrinsic value of one NOTV stock under the base case scenario is HIDDEN Compared to the current market price of 2.68 USD, Inotiv, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NOTV

image
FINANCIALS
572 M REVENUE
4.52%
-81.5 M OPERATING INCOME
-196.79%
-105 M NET INCOME
68.90%
27.9 M OPERATING CASH FLOW
634.46%
-28.8 M INVESTING CASH FLOW
91.38%
15.9 M FINANCING CASH FLOW
-92.19%
106 M REVENUE
-11.13%
-20.8 M OPERATING INCOME
48.65%
-26.1 M NET INCOME
45.74%
-14.8 M OPERATING CASH FLOW
-87.52%
-2.95 M INVESTING CASH FLOW
35.62%
-795 K FINANCING CASH FLOW
32.23%
Balance Sheet Decomposition Inotiv, Inc.
image
Current Assets 214 M
Cash & Short-Term Investments 35.5 M
Receivables 90.4 M
Other Current Assets 87.9 M
Non-Current Assets 643 M
Long-Term Investments 3.68 M
PP&E 230 M
Other Non-Current Assets 409 M
Current Liabilities 132 M
Accounts Payable 32.6 M
Short-Term Debt 18.2 M
Other Current Liabilities 81.4 M
Non-Current Liabilities 456 M
Long-Term Debt 399 M
Other Non-Current Liabilities 56.4 M
EFFICIENCY
Earnings Waterfall Inotiv, Inc.
image
Revenue 572 M
Cost Of Revenue 407 M
Gross Profit 165 M
Operating Expenses 247 M
Operating Income -81.5 M
Other Expenses 23.4 M
Net Income -105 M
RATIOS
28.90% GROSS MARGIN
28.90%
-14.23% OPERATING MARGIN
-14.23%
-18.37% NET MARGIN
-18.37%
-39.06% ROE
-39.06%
-12.28% ROA
-12.28%
-10.63% ROIC
-10.63%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Inotiv, Inc.
image
Net Income -105 M
Depreciation & Amortization 54.7 M
Capital Expenditures -27.5 M
Stock-Based Compensation 7.84 M
Change in Working Capital 17 M
Others 66.5 M
Free Cash Flow 380 K
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Inotiv, Inc.
image
Wall Street analysts predict an average 1-year price target for NOTV of $6.5 , with forecasts ranging from a low of $4 to a high of $10 .
NOTV Lowest Price Target Wall Street Target
4 USD 49.25%
NOTV Average Price Target Wall Street Target
6.5 USD 142.54%
NOTV Highest Price Target Wall Street Target
10 USD 273.13%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Inotiv, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
164 K USD 2
9-12 MONTHS
Date Value Insider Amount Avg Price
5 years ago
Jun 07, 2019
Bought 14.9 K USD
Leasure Robert Jr.
President and CEO
+ 7500
1.9819 USD
11 months ago
Dec 14, 2023
Bought 14.1 K USD
Garrett Michael
Chief Commercial Officer
+ 5000
2.829 USD
11 months ago
Dec 14, 2023
Bought 150 K USD
Beattie John Gregory
Chief Operating Officer
+ 47966
3.1238 USD
1 year ago
Mar 14, 2023
Bought 25 K USD
Sagartz John E
Chief Strategy Officer
+ 5100
4.91 USD
1 year ago
Feb 22, 2023
Bought 35 K USD
Beattie John Gregory
Chief Operating Officer
+ 5000
6.99 USD
1 year ago
Dec 09, 2022
Sell 12.4 K USD
Pitchford William D
Chief Human Resources Officer
- 2123
5.8246 USD
1 year ago
Dec 01, 2022
Sell 6.12 K USD
Neff R Matthew
Director
- 1000
6.12 USD
2 years ago
Nov 01, 2022
Sell 10.6 K USD
Neff R Matthew
Director
- 500
21.1201 USD
2 years ago
Nov 01, 2022
Sell 10.6 K USD
Neff R Matthew
Director
- 500
21.1261 USD
2 years ago
Oct 17, 2022
Sell 19.1 K USD
Neff R Matthew
Director
- 1000
19.1 USD
2 years ago
Mar 15, 2022
Bought 76.3 K USD
Harkness James
Chief Operating Officer, RMS
+ 4049
18.84 USD
2 years ago
Feb 18, 2022
Bought 26.4 K USD
Davis Gregory Cole
Director
+ 1250
21.12 USD
2 years ago
Feb 18, 2022
Bought 59.8 K USD
Davis Gregory Cole
Director
+ 2500
23.9255 USD
2 years ago
Feb 17, 2022
Bought 25.7 K USD
Davis Gregory Cole
Director
+ 1250
20.571 USD
2 years ago
Feb 17, 2022
Bought 115 K USD
Leasure Robert Jr.
President and CEO
+ 5000
23.0262 USD
2 years ago
Feb 17, 2022
Bought 50 K USD
Sagartz John E
Chief Strategy Officer
+ 2506
19.9516 USD
2 years ago
Dec 22, 2021
Sell 132 K USD
Downing Philip A
Sr. VP, Preclinical Srvcs.
- 3057
43.0412 USD
3 years ago
Jun 07, 2021
Bought 50 K USD
Sagartz John E
Chief Strategy Officer
+ 1742
28.7 USD
3 years ago
May 28, 2021
Bought 49.9 K USD
Sagartz John E
Chief Strategy Officer
+ 2012
24.78 USD
3 years ago
May 27, 2021
Bought 120 USD
Sagartz John E
Chief Strategy Officer
+ 5
24 USD
7. News
Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, has amended certain terms of its Credit Agreement. In addition, Inotiv has closed the sale of $22.6 million aggregate principal amount of 15% Senior Secured Second Lien PIK Notes due February 2027 (the “Second Lien Notes”), and warrants to purchase common shares, to certain investors in a private offering. globenewswire.com - 2 months ago
Inotiv to Participate in the 8th Annual Lake Street Best Ideas Growth Conference WEST LAFAYETTE, Ind., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., Inotiv's President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the 8th Annual Lake Street Best Ideas Growth Conference on Thursday, September 12, 2024, in New York City. globenewswire.com - 2 months ago
Inotiv, Inc. (NOTV) Q3 2024 Earnings Call Transcript Inotiv, Inc. (NASDAQ:NOTV ) Q3 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Bob Yedid - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer John Sagartz - Chief Strategy Officer Conference Call Participants Matt Hewitt - Craig-Hallum Nelson Cox - Lake Street Capital Markets Dave Windley - Jefferies Eric Coldwell - Baird Operator Good day, everyone and welcome to this Inotiv Third Quarter Earnings Conference Call. [Operator Instructions] And it's now my pleasure to turn the floor over to Mr. seekingalpha.com - 3 months ago
Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates Inotiv, Inc. (NOTV) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.07 per share a year ago. zacks.com - 3 months ago
Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024 WEST LAFAYETTE, Ind., July 25, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, on Thursday, August 8, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. globenewswire.com - 3 months ago
3 Breakout Stocks to Buy Before They Make Headlines In the current volatile market, breakout stocks with sound growth potential are most important for those investors looking to maximize returns. The list includes three such standout companies that can deliver substantial gains. investorplace.com - 4 months ago
3 Undervalued Stocks Primed for a 2X Return For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in a sharp investment plan. investorplace.com - 4 months ago
Inotiv, Inc. Provides Business Updates WEST LAFAYETTE, Ind., June 10, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provided the following business updates: globenewswire.com - 5 months ago
Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility Company reaffirms commitment to maintaining appropriate standards of animal welfare Company reaffirms commitment to maintaining appropriate standards of animal welfare globenewswire.com - 5 months ago
Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences WEST LAFAYETTE, Ind., May 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the upcoming 21st Annual Craig Hallum Institutional Investor Conference and Jefferies Global Healthcare Conference. globenewswire.com - 5 months ago
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Inotiv, Inc. (NOTV) NEW YORK--(BUSINESS WIRE)-- #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV). The investigation concerns whether Inotiv and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On May 13, 2024, Inotiv disclosed that it is unable to timely file its Quarterly Report on Form 10-Q for the quarter e. businesswire.com - 6 months ago
Inotiv, Inc. (NOTV) Q2 2024 Earnings Call Transcript Inotiv, Inc. (NASDAQ:NOTV ) Q2 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Bob Yedid - Investor Relations Bob Leasure - President and CEO Beth Taylor - Chief Financial Officer Conference Call Participants Dave Windley - Jefferies Matt Hewitt - Craig-Hallum Frank Takkinen - Lake Street Capital Markets Operator Good afternoon ladies and gentlemen and welcome to the Inotiv's Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 6 months ago
8. Profile Summary

Inotiv, Inc. NOTV

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 69.7 M
Dividend Yield 0.00%
Description Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Contact 2701 Kent Avenue, West Lafayette, IN, 47906-1382 https://www.inotivco.com
IPO Date Nov. 25, 1997
Employees 1955
Officers Dr. John E. Sagartz D.V.M., DiplomateACVP, Ph.D. Chief Strategy Officer & Director Mr. John Gregory Beattie DSA Chief Operating Officer of DSA Ms. Andrea Castetter SVice President of General Counsel, Corporate Secretary & Chief Compliance Officer Ms. Lizanne Muller Group President of RMS Dr. Adrian Hardy Ph.D. Chief Commercial Officer Mr. Jeffrey Arthur Krupp Chief Human Resources Officer Dr. Peter T. Kissinger Founder, Chairman Emeritus & Scientific Advisor Ms. Beth A. Taylor CPA Senior Vice President of Finance & Chief Financial Officer Mr. Robert W. Leasure Jr. President, Chief Executive Officer & Director Mr. Brennan Freeman Vice President of Finance, Principal Accounting Officer & Corporate Controller